General MedicationsORALGeneric

ABACAVIR AND LAMIVUDINE

ABACAVIR; LAMIVUDINE

Standard Dose

120MG;60MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview ABACAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 208775 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION;ORAL - 120MG;60MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2017-04-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 208775 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION;ORAL - 120MG;60MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2017-04-06 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.